PMA device
FC2 Female Condom
Clear Future, Inc. · Single-Use Internal Condom (MBU, Class II) · First FDA decision Mar 10, 2009, newest Jun 23, 2017ContraceptionHIV, hepatitis and sexually transmitted infections
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
7
Naming "FC2 Female"
MAUDE reports
0
Brand "FC2 Female", since 2015
PubMed studies
6
Mentioning "FC2 Female"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing FC2 Female Condom
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- FC2 FEMALE CONDOMPMA supplement
P080002-S002 · Decided Jun 23, 2017 · 479 days after receipt · Normal 180 Day Track
Device type: Single-use internal condom (MBU) · Obstetrics & Gynecology
- FC2 FEMALE CONDOMPMA supplement
P080002-S001 · Decided Sep 23, 2011 · 196 days after receipt · Normal 180 Day Track
Device type: Single-use internal condom (MBU) · Obstetrics & Gynecology
P080002 · Decided Mar 10, 2009 · 427 days after receipt
Device type: Single-use internal condom (MBU) · Obstetrics & Gynecology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "FC2 Female", any status and sponsor, newest update first.
- Functional Performance and Acceptability Evaluation of the Miss Liberty Female Condom Compared to the FC2 Female CondomPivotal-lookingCompleted
University of Witwatersrand, South AfricaAcademic, hospital or other
NCT06821152 · 235 participants · Start May 21, 2025 · Primary completion Oct 15, 2025
Device: Miss Liberty Condom; FC2 condom · For: Functional Performance
Sites: Durban, South Africa
- Assessing Preference for 3 Female Condoms: A Comparative Evaluation of the PATH Woman's Condom, FC2 and the Reddy 6Pivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT01452503 · 170 participants · Start May 2007 · Primary completion Feb 2008
Device: Path Women's Condom; FC2 female condom and 1 more · For: Contraception
Sites: Durban, South Africa
- Comparative Study of the Contraceptive Efficacy of the Cupid, Cupid 2 and FC2 Female CondomPivotal-lookingCompleted
Prof Mags BeksinskaAcademic, hospital or other
NCT04233632 · 400 participants · Start Nov 27, 2019 · Primary completion Nov 10, 2021
Device: FC2 Condom; Cupid Condom and 1 more · For: Pregnancy Prevention
Sites: Durban, South Africa
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "FC2 Female", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MBU
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "FC2 Female"[tiab]. The summary above synthesizes these.
- Functional performance of the Wondaleaf condom: A crossover, noninferiority, randomized clinical trial.
Beksinska M, Mphili N, Smit J · Int J STD AIDS · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Performance and Acceptability of the FC2 Female Condom When Used With and Without a Silicone Placebo Vaginal Ring-A Randomized, Crossover Trial.
Nel A, Malherbe M, van Niekerk N, et al. · J Acquir Immune Defic Syndr · 2020Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Functional performance study of an adapted design of the woman's condom: a crossover, noninferiority, randomized clinical trial.
Beksinska M, Greener R, Mphili N, et al. · Eur J Contracept Reprod Health Care · 2019Comparative Study, Equivalence Trial
- FDA notifications. FC2 female condom receives FDA approval.
AIDS Alert · 2009Newspaper Article
- Female condom acceptability and use amongst young women in Botswana.
Mokgetse M, Ramukumba MM · Curationis · 2018
- A randomized noninferiority crossover controlled trial of the functional performance and safety of new female condoms: an evaluation of the Velvet, Cupid2, and FC2.
Beksinska M, Greener R, Kleinschmidt I, et al. · Contraception · 2015Randomized Controlled Trial, Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.